Bolt Biotherapeutics (BOLT) risk factors, FY2025 10-K

Risks Related to Our Financial Position and Need for Additional Capital

1. 01We have a limited operating history and have incurred significant losses since inception, and we anticipate that we may continue to incur losses for the foreseeable future and may never achieve or maintain profitability
2. 02incur additional legal, accounting and other expenses in operating our business, including the additional costs associated with operating as a public company
3. 03We will need substantial funding to pursue our business objectives. If we are unable to raise capital when needed or on terms favorable to us, we could be forced to delay, reduce or terminate our product development and other operations21% rewritten
4. 04the extent to which we acquire or in-license other product candidates and technologies and associated intellectual property
5. 05Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish proprietary rights
6. 06International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospectsNew
7. 07We might not be able to utilize a significant portion of our net operating loss, or NOL, carryforwards66% rewritten
8. 08the use of NOL carryforwards are suspended or otherwise limited, such as recent California legislation limiting the usability of NOL carryforwards for tax years beginning in 2020 and before 2022New

Risks Related to the Development of Our Product Candidates

1. 09If none of our product candidates, including those in our collaborations, obtain regulatory approval and are successfully commercialized in one or more indications, or we or our collaboration partners experience significant delays in doing so, we may never generate any product revenue or become profitable
2. 10obtaining licenses to any third-party intellectual property we deem necessary or desirable
3. 11We are currently developing, and in the future may develop, product candidates in combination with other therapies and that may expose us to additional risks
4. 12We may seek accelerated approval for some or all of our product candidates from the FDA, however, the FDA may disagree and may require completion of additional clinical trials before considering a Biologics License Application, or BLA, for review
5. 13Clinical trials are very expensive, time-consuming and difficult to design and implement, and involve uncertain outcomes. Furthermore, results of earlier preclinical studies and clinical trials may not be predictive of results of future preclinical studies or clinical trials
6. 14We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities
7. 15changes in regulatory requirements and guidance that require amending or submitting new clinical protocols
8. 16Our drug development costs will also increase if we experience delays in testing or obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all
9. 17We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
10. 18If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the drug could be compromised
11. 19harm to our reputation and resulting harm to physician or patient acceptance of our products
12. 20If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
13. 21the risk that patients enrolled in clinical trials will drop out of the trials before completion
14. 22We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims37% rewritten
15. 23liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our product candidatesNew

Risks Related to Commercialization of Our Product Candidates

1. 24We have never commercialized a product candidate and we may lack the necessary expertise, personnel and resources to successfully commercialize on our own or together with collaborators, any of our products that receive regulatory approval
2. 25We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do
3. 26Our competitors may succeed in developing, acquiring or licensing, on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop. In addition, most of these companies have substantially greater sales, marketing and other experience and reserves than we do
4. 27Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success
5. 28Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenueNew
6. 29Even if we receive marketing approval for any of our product candidates, we may not achieve market acceptance, which would limit the revenue that we can generate from sales of any of our approved product candidates
7. 30the likelihood that the FDA may impose additional requirements that limit the promotion, advertising, distribution or sales of our product candidates28% rewritten
8. 31biopharmaceutical industry generally could also result in greater governmental regulation and stricter labeling requirementsNew
9. 32Even if we obtain regulatory approval for our product candidates, they will remain subject to ongoing regulatory oversight
10. 33If any of these events occurs, our ability to sell such product may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could harm our business, financial condition, results of operations and prospects
11. 34unforeseen costs and expenses associated with creating an independent sales and marketing organization77% rewritten

Risks Related to Our Dependence on Third Parties

1. 35We do not have our own manufacturing capabilities and rely on third parties to produce clinical and commercial supplies of BDC-4182 and our other current and future product candidates
2. 36other events or factors, including those resulting from geopolitical events, or responses to these events
3. 37We intend to conduct our future clinical trials using our own clinical resources while also leveraging expertise and assistance from CROs as appropriate. We do not currently have the ability to independently conduct large-scale clinical trials, such as a Phase 3 clinical trial, without outside assistance
4. 38If we are not able to maintain our current collaborations and establish further collaborations, we may have to alter some of our future development and commercialization plans

Risks Related to Regulatory Compliance

1. 39Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may charge for such product candidates43% rewritten
2. 40foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers40% rewritten

Risks Related to Our Intellectual Property

1. 41If we are unable to obtain, maintain and protect sufficient patent and other intellectual property rights for our product candidates and technology, or if the scope of patent and other intellectual property rights obtained is not sufficiently broad, we may not be able to compete effectively in our market
2. 42The patent protection we obtain for our product candidates and technology may be challenged or not sufficient to provide us with any competitive advantage
3. 43the effects of termination
4. 44Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed49% rewritten
5. 45We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful, and issued patents covering our technology and product candidates could be found invalid or unenforceable if challenged26% rewritten
6. 46We may not be able to protect our intellectual property rights throughout the world
7. 47We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop and market our product candidates
8. 48If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed
9. 49Patent terms may be inadequate to protect the competitive position of our product candidates for an adequate amount of time
10. 50Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
11. 51Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements
12. 52Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could negatively impact the success of our business
13. 53We may be subject to claims by third parties asserting that we or our employees have infringed upon, misappropriated or otherwise violated their intellectual property rights, or claiming ownership of what we regard as our own intellectual property82% rewritten
14. 54property, including trade secrets or other proprietary information, of any such individual’s former employer. Litigation may be necessary to defend against these claimsNew
15. 55Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities
16. 56If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
17. 57We may not be able to protect and enforce our trademarks and trade names or build name recognition in our markets of interest thereby harming our competitive position
18. 58Intellectual property rights do not necessarily address all potential threats

Risks Related to Our Business Operations, Employee Matters and Managing Growth

1. 59Our future success depends on our ability to retain executives, key employees, consultants and advisors and to attract, retain and motivate qualified personnel
2. 60Replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval for and commercialize our product candidates
3. 61We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
4. 62Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements
5. 63Our international operations may expose us to business, regulatory, political, operational, financial, pricing and reimbursement risks associated with doing business outside of the United States
6. 64certain expenses including, among others, expenses for travel, translation and insurance; and
7. 65Our internal computer systems, or those used by our CROs or other contractors or consultants, may fail or experience security breaches or other unauthorized or improper access

Risks Related to Our Common Stock

1. 66The trading price of the shares of our common stock may be volatile, and purchasers of our common stock could incur substantial losses
2. 67other events or factors, many of which are beyond our control
3. 68Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price40% rewritten
4. 69If equity research analysts do not publish research or reports, or publish unfavorable research or reports about us, our business or our market, our stock price and trading volume could decline
5. 70A significant portion of our total outstanding common stock may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well
6. 71Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock
7. 72require the approval of our board of directors or the holders of at least 66 2/3% of our outstanding shares of common stock to amend our bylaws and certain provisions of our certificate of incorporation
8. 73We will incur costs and demands upon our management as a result of complying with the laws and regulations affecting public companies in the United States, which may harm our business
9. 74We are an “emerging growth company” and a “smaller reporting company,” and as a result of the reduced reporting requirements applicable to “emerging growth companies” and “smaller reporting companies,” our common stock may be less attractive to investors
10. 75If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate consolidated financial statements on a timely basis could be impaired
11. 76Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment40% rewritten
12. 77between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employeesNew
13. 78any action asserting a claim against us that is governed by the internal-affairs doctrine